C4 Therapeutics (CCCC) Operating Expenses (2019 - 2026)

C4 Therapeutics' Operating Expenses history runs 8 years deep, the most recent figure standing at $33.9 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 6.77% year-over-year to $33.9 million in Q1 2026; TTM through Mar 2026 was $148.7 million, a 4.89% decrease from a year earlier, with the FY2025 full-year figure at $151.2 million, down 2.6% from the prior year.
• Operating Expenses declined to $33.9 million in Q1 2026 per CCCC's latest filing, from $34.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $45.6 million in Q3 2025 and bottomed at $33.4 million in Q2 2024.
• The 5-year median for Operating Expenses is $39.2 million (2022), against an average of $38.9 million.
• Across the five-year window, Operating Expenses soared 39.69% in 2022 and retreated 20.34% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $41.1 million in 2022, then slipped by 1.12% to $40.7 million in 2023, then climbed by 5.4% to $42.9 million in 2024, then decreased by 20.34% to $34.2 million in 2025, then decreased by 0.66% to $33.9 million in 2026.
• Per Business Quant, the three latest CCCC Operating Expenses figures stand at $33.9 million (Q1 2026), $34.2 million (Q4 2025), and $45.6 million (Q3 2025).